(*contributed equally to this work) Published: Vol 8, Iss 17, Sep 5, 2018 DOI: 10.21769/BioProtoc.2991 Views: 10433
Reviewed by: Xi FengSubhra Prakash HuiAnonymous reviewer(s)
Protocol Collections
Comprehensive collections of detailed, peer-reviewed protocols focusing on specific topics
Related protocols
Melanoma Stem Cell Sphere Formation Assay
Alessandra Tuccitto [...] Michela Perego
Apr 20, 2017 14089 Views
Isolation and Culture of Neural Stem/Progenitor Cells from the Hippocampal Dentate Gyrus of Young Adult and Aged Rats
Mina Afhami [...] Koorosh Shahpasand
Oct 5, 2023 1093 Views
Derivation and Culture of Enriched Phrenic-Like Motor Neurons From Human iPSCs
Louise Thiry [...] Stefano Stifani
Jul 5, 2025 954 Views
Abstract
Glioma stem cells (GSC) grown as neurospheres exhibit similar characteristics to neural stem cells (NSC) grown as neurospheres, including the ability to self-renew and differentiate. GSCs are thought to play a role in cancer initiation and progression. Self-renewal potential of GSCs is thought to reflect many characteristics associated with malignancy, including tumor recurrence following cytotoxic therapy due to their proliferative dormancy and capacity to allow for the development of resistant tumor cell sub-clones due to mutations acquired during their differentiation. Here, we demonstrate that using extreme limiting dilution analysis (ELDA), subtle differences in the frequency of sphere-forming potential between PI3K-mutant oncogenic NSCs and non-oncogenic NSCs can be measured, in vitro. We further show how ELDA can be used on cells, before and after forced differentiation to amplify inherent differences in sphere-forming potential between mutant and control NSCs. Ultimately, ELDA exploits a difference in the ability of a single or a few seeded stem cells to self-renew, divide and form neurospheres. Importantly, the assay also allows a comparison between genetically distinct cells or between the same cells under different conditions, where the impact of target-specific drugs or other novel cancer stem cell therapies can be tested.
Keywords: Stem cellsBackground
Glioblastoma (GBM) is one of the most common types of brain cancer with an extremely poor prognosis (Kaye and Morokoff, 2014). GBM treatment success or failure is determined by a complex biology due to the underlying genetics and epigenetics which regulate many signal transduction pathways, which in turn govern pro-oncogenic tumor cell behaviors and ultimately response/resistance to treatments. One of the major pathways regulating GBM cell behavior involves hyperactivation of PI3K signaling due mutations involving one or more pathway factors including the epidermal growth factor receptor (EGFR), the PI3K catalytic subunit encoded by the PIK3CA gene and deletion of the PI3K pathway negative regulator and tumor suppressor, Phosphatase and Tensin Homolog (PTEN) (Mantamadiotis, 2017). Using a genetically engineered mouse model, our recent study demonstrated that PI3K mutations, specifically targeting the Pik3ca and Pten genes in neural stem/progenitor cells (NSPs) can trigger the development of aggressive brain tumors, in vivo (Daniel et al., 2017 and 2018). In vitro analysis of NSCs isolated from mutant and wild-type mice revealed intrinsic cellular differences between genotypes, including sphere forming potential, which is a correlate of stem cell potential. This protocol describes the method used to investigate neural stem cell potential via established and variations on established methods. Extreme limiting dilution analysis (ELDA) can be used to analyze stem cell self-renewal ability and has been widely used in the stem cell field (Shackleton et al., 2006; Quintana et al., 2008; Vaillant et al., 2008). Subtle differences between NSCs or GSCs can be quantified by ELDA using a freely available webtool (Hu and Smyth, 2009). Moreover, we present a variation in stem cell potential analysis by including an intermediate differentiation step between ELDA measurements, which revealed more substantial differences in sphere forming potential between mutant and wild-type mouse NSCs, compared to performing ELDA alone, with cells which had not undergone forced differentiation. The forced differentiation step measures the inherent stability of NSCs and GBM-like NSCs, which maintain neurosphere forming potential following differentiation; stability which may correlate with faster disease relapse/recurrence following therapy.
Materials and Reagents
Equipment
Software
Procedure
Data analysis
Notes
ELDA assay can be used to study self-renewal ability of any type of cells. With ELDA software, the frequency of sphere-forming cells can be generated and compared between multiple cell sub-populations and different treatments.
Recipes
Acknowledgments
This work was supported by the CASS Foundation Grant (#7491). A brief description of the protocol described in this article originally appeared in Daniel et al. (2017 and 2018). The original ELDA protocol is described in Hu and Smyth, 2009.
Competing interests
The authors declare no conflicts of interest.
References
Article Information
Copyright
© 2018 The Authors; exclusive licensee Bio-protocol LLC.
How to cite
Nguyen, H. P., Daniel, P. M., Filiz, G. and Mantamadiotis, T. (2018). Investigating Neural Stem Cell and Glioma Stem Cell Self-renewal Potential Using Extreme Limiting Dilution Analysis (ELDA). Bio-protocol 8(17): e2991. DOI: 10.21769/BioProtoc.2991.
Category
Stem Cell > Adult stem cell > Neural stem cell
Cancer Biology > Cancer stem cell > Cell biology assays
Cell Biology > Cell-based analysis > Non-adherent culture
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.
Share
Bluesky
X
Copy link